AstraZeneca (AZN) Receives a Buy from Citi
In a report released today, Graham Parry from Citi maintained a Buy rating on AstraZeneca, with a price target of £175.00.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Parry is ranked #6661 out of 12322 analysts.
In addition to Citi, AstraZeneca also received a Buy from J.P. Morgan’s Richard Vosser in a report issued yesterday. However, on June 30, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).
Based on AstraZeneca’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p15.29 billion and a net profit of p3.08 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p3 billion
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.
Read More on GB:AZN:
Disclaimer & DisclosureReport an Issue
- Appeals court upholds win for AstraZeneca in Pfizer patent fight, Reuters says
- Ionis Pharmaceuticals price target lowered to $86 from $105 at Needham
- AstraZeneca’s Real-World Lung Cancer Study in China: What Investors Should Watch
- AstraZeneca Advances Surovatamig Trial in High-Risk Blood Cancer
- AstraZeneca Extends Anifrolumab Access With New ROSY-S Rollover Study
